The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients

Canadian Journal of Cardiology

Volumn 23, Issue 8, 2007, Pages 651-655

  Tarighi, Bahman ^a   Kurum, Turhan ^a   Demir, Muzaffer ^a   Azcan, Sen Nur ^a  

^a TRAKYA UNIVERSITY   (Turkey)

Author keywords

Fibrinolytic system; Hypertension; Nebivolol

Indexed keywords

FIBRINOGEN; NEBIVOLOL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EUGLOBULIN LYSIS TEST; FEMALE; HEART RATE; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 34547540683     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(07)70227-1     Document Type: Article

References (43)

1. Vyssoulis GP, Marinakis AG, Aznaouridis KA, et al. The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: Effects of smoking. Am J Hypertens 2004; 17:582-9.
2. Selwyn AP, Kinlay S, Creaget M, Libby P, Ganz P. Cell dysfunction in atherosclerosis and the ischemic manifestations of coronary artery disease. Am J Cardiol 1997;79:17-23.
3. Lijnen HR, Collen D. Endothelium in hemostasis and thrombosis. Prog Cardiovasc Dis 1997;39:343-50.
4. Panza JA, Quyyumi AA, Brush JE Jr, Ebstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22-7.
5. Lip G, Blarm A, Jones AF, Lip PL, Beevers DG. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol 1997;80:1566-71.
6. Eliasson M, Jansson J, Nilsson P, Asplund K. Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden. J Hypertens 1997;15:349-56.
7. Muiesan ML, Salvetti M, Monteduro C, et al. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension 1999;33:575-80.
8. 1-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Nitric Oxide 2002;7:75-82.
9. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: A randomized, double-blind, crossover study. Circulation 2001;104:511-4.
10. Van Bortel LM, Breed JG, Joosten J, Kragten JA, Lustermans FA, Mooij JMV. Nebivolol in hypertension: A double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J Cardiovasc Pharmacol 1993;21:856-62.
11. Brett SE, Forte PJ, Chowienczyk NB, Benjamin N, Ritter JM. Comparison of the effects of nebivolol and bisoprolol on systemic vascular resistance in patients with essential hypertension: Beta-blockade and haemodynamics in hypertension. Clin Drug Investig 2002;22:355-9.
12. Swales JD, Sever PS, Peart WS. Drug treatment. In: Swales JD, Sever PS, Peart WS, eds. Hypertension. New York: Gower Medical Publishing, 1991:9.1-9.33.
13. Lip GY, Blann AD. Does hypertension confer a prothrombotic state? Virchow's triad revisited. Circulation 2000; 101:218-20.
14. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-906.
15. Makris TK, Tsoukala C, Krespi P, et al. Haemostasis balance disorders in patients with essential hypertension. Thromb Res 1997;88:99-107.
16. Kennedy BF, Farag NH, Ziegler MG, Mills PJ. Relationship of systolic blood pressure with plasma homosysteine: Importance of smoking status. J Hypertens 2003;21:1307-12.
17. Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997;17:3321-5.
18. Stehouwer CDA. Is measurement of endothelial dysfunction clinically useful? Eur J Clin Invest 1999;29:459-61.
19. Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241-7.
20. Winther K. The effect of beta-blockade on platelet function and fibrinolytic activity. J Cardiovasc Pharmacol 1987;10(Suppl 2):S94-8.
21. Winther K, Hedman C. Beta-adrenoceptor blockade, platelets, and rheologic factors. Cephalagia 1986;6(Suppl 5):33-9.
22. Gleerup G, Hedner T, Hjorting Hansen E, Windier K. Does antihypertensive therapy affect the natural protection against thrombosis? J Cardiovasc Pharmacol 1991; 18(Suppl 3):S34-6.
23. Larsson PT, Wiman B, Olsson G, Angelin B, Hjemdahl P. Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis. Thromb Haemost 1990;63:482-7.
24. Teger-Nilsson AC, Dahlöf C, Haglund E, Hedman C, Olsson G, Ablad B. Influence of metoprolol CR/ZOK on plasminogen activator inhibitor (PAI-1) in man: A pilot study. J Clin Pharmacol 1990;30(2 Suppl):S132-7.
25. Jimenez AH, Tofler GH, Chen X, Stubbs ME, Solomon HS, Muller JE. Effects of nadolol on hemodynamic and hemostatic responses to potential mental and physical triggers of myocardial infarction in subjects with mild systemic hypertension. Am J Cardiol 1993;72:47-52.
26. Jansson JH, Johansson B, Boman K, Nilsson TK. Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol. Eur J Clin Pharmacol 1991;40:321-6.
27. 2-adrenergic receptor-mediated nitric oxide production. Circulation 2000;102:677-84.
28. Mollnau H, Schulz E, Daiber A, et al. Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol 2003;23:615-21.
29. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med 1993;118:956-63.
30. Lee AJ. The role of rheological and haemostatic factors in hypertension. J Hum Hypertens 1997;11:767-76.
31. Vaya A, Martinez M, Garcia J, Labios M, Aznar J. Hemorheological alterations in mild essential hypertension. Thromb Res 1992;66:223-9. (Erratum in 1993;72:473).
32. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990;227:273-8.
33. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-41.
34. Makris TK, Stavroulakis GA, Krespi PG, et al. Fibrinolytic/hemostatic variables in arterial hypertension: Response to treatment with irbesartan or atenolol. Am j Hypertens 2000;13:783-8.
35. Linde T, Sandhagen B, Hagg A, Morlin C, Danielson BG. Decreased blood viscosity and serum levels of erythropoietin after anti-hypertensive treatment with amlodipine or metoprolol: Results of a cross-over study. J Hum Hypertens 1996;10:199-205.
36. Haenni A, Lithell H. Uradipil treatment decreases plasma fibrinogen concentration in essential hypertension. Metabolism 1996;45:1221-9.
37. Herrmann JM, Mayer EO. A long-term study of the effects of celiprolol on blood pressure and lipid-associated risk factors. Am Heart J 1988; 116:1416-21.
38. Caimi G, Catania A, Frazzetta F, Capobianco D, Sarno A. Essential hypertension. The behaviour of the haemorheological determinants and their trends during beta-blocker treatment. Jpn Heart J 1983;24:723-9.
39. Ding YA, Law HW, Chou TC. Comparison of cilazapril and nifedipine retard on ambulatory blood pressure, metabolic, rheological and platelet function in hypertensive patients. J Hum Hypertens 1994;8:137-43.
40. Fogari R, Zoppi A, Lazzari P, et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 1998;32:616-20.
41. Fanari P, Somazzi R, Nasrawi F, et al. Haemorheological changes in obese adolescents after short-time diet. Int J Obes Relat Metab Disord 1993;17:487-94.
42. Rillaerts E, Van Gaal L, Xiang DZ, Vansant G, De Leeuw I. Blood viscosity in human obesity: Relation to glucose tolerance and insulin status. Int J Obes 1989;13:739-45.
43. Tomiyama H, Kimura Y, Mitsuhashi H, et al. Relationship between endothelial function and fibrinolysis in early hypertension. Hypertension 1998;31:321-7.